Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel in HER2-Positive Metastatic Breast Cancer
CTR20131049Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pertuzumab in breast cancer, sponsored by Roche. Started Mar 2015; status: active.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20131049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131049.